![Helen Pearson](https://profiles-cardiff.imgix.net/attachments/1158?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Helen Pearson
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Helen Pearson
Uwch Ddarlithydd mewn Canser y Prostad
Ysgol y Biowyddorau
Trosolwg
Prostate Cancer Translational Research Laboratory
European Cancer Stem Cell Research Institute, Cardiff University, Department of Biomedicine, School of Biosciences, Cardiff University
Prostate cancer arises from multiple complex cellular processes that remain to be fully understood. Dr Pearson’s research into prostate cancer integrates basic molecular and cellular biology with preclinical trials to advance our understanding of prostate cancer biology, and to translate laboratory studies into improvements in patient care and outcome. To address this, the research undertaken incorporates the development and application of innovative preclinical model systems in collaboration with researchers, clinicians and industry.
Cyhoeddiad
2025
- Brajdic, L. et al. 2025. Cutibacterium acnes: An emerging prostate cancer pathogen. Biology 15 (1) 30. (10.3390/biology15010030)
- Hodson, K. et al. 2025. Targeting cancer with Paris' arrow: An updated perspective on targeting Wnt Receptor Frizzled 7. Sci 7 (2) 61. (10.3390/sci7020061)
2024
- Al-janabi, H. et al., 2024. Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer 12 (7) e009368. (10.1136/jitc-2024-009368)
- Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13 (8) 673. (10.3390/cells13080673)
2023
- Chessa, T. A. et al., 2023. PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate. Molecular Cell 83 (16), pp.2991-3009. E13. (10.1016/j.molcel.2023.07.015)
2022
- Owen, J. S. , Clayton, A. and Pearson, H. B. 2022. Cancer-associated fibroblast heterogeneity, activation and function: implications for prostate cancer. Biomolecules 13 (1) 67. (10.3390/biom13010067)
- Koushyar, S. et al. 2022. Exploring the Wnt pathway as a therapeutic target for prostate cancer. Biomolecules 12 (2) 309. (10.3390/biom12020309)
2020
- Turnham, D. J. et al. 2020. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9 (11) 2342. (10.3390/cells9112342)
- Shorning, B. Y. et al. 2020. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. International Journal of Molecular Sciences 21 (12) 4507. (10.3390/ijms21124507)
2019
- Flanagan, D. J. et al., 2019. Frizzled-7 is required for Wnt signaling in gastric tumours with and without Apc mutations. Cancer Research 79 (5), pp.970-981. (10.1158/0008-5472.CAN-18-2095)
2018
- Pearson, H. B. et al. 2018. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth. Cancer Discovery 8 (6), pp.764-779. (10.1158/2159-8290.CD-17-0867)
2017
- Martin, A. C. B. et al., 2017. [10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo. Oncotarget 8 (42), pp.72260-72271. (10.18632/oncotarget.20139)
- Liu, D. S. et al., 2017. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications 8 14844. (10.1038/ncomms14844)
2016
- Rebello, R. J. et al., 2016. The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. Clinical Cancer Research 22 (22), pp.5539-5552. (10.1158/1078-0432.CCR-16-0124)
- Denoyer, D. et al., 2016. Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget 7 (24), pp.37064-37080. (10.18632/oncotarget.9245)
2015
- Wölwer, C. B. et al., 2015. A chemical screening approach to identify novel key mediators of erythroid enucleation. PLoS ONE 10 (11) e0142655. (10.1371/journal.pone.0142655)
- Pearson, H. B. et al. 2015. The polarity protein Scrib mediates epidermal development and exerts a tumor suppressive function during skin carcinogenesis. Molecular Cancer 14 169. (10.1186/s12943-015-0440-z)
- Sampurno, S. et al., 2015. Myb via TGFβ is required for collagen type 1 production and skin integrity. Growth Factors 33 (2), pp.102-112. (10.3109/08977194.2015.1016222)
- Johnstone, C. N. et al., 2015. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Disease Models and Mechanisms 8 (3), pp.237-251. (10.1242/dmm.017830)
- Takizawa, I. et al., 2015. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget 6 (2), pp.604-616. (10.18632/oncotarget.2820)
2014
- Elsum, I. A. et al., 2014. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo. Oncogene 33 (48), pp.5523-5533. (10.1038/onc.2013.498)
- Gödde, N. J. et al., 2014. Dissecting the role of polarity regulators in cancer through the use of mouse models. Experimental Cell Research 328 (2), pp.249-257. (10.1016/j.yexcr.2014.08.036)
- DiTommaso, T. et al., 2014. Keratin 76 is required for tight junction function and maintenance of the skin barrier. PLoS Genetics 10 (10) e1004706. (10.1371/journal.pgen.1004706)
- Phesse, T. J. et al. 2014. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration. Science Signaling 7 (345) ra92. (10.1126/scisignal.2005411)
- Phesse, T. J. et al. 2014. Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell Death and Differentiation 21 (6), pp.956-966. (10.1038/cdd.2014.15)
- Godde, N. J. et al., 2014. Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland. PLoS Genetics 10 (5) e1004323. (10.1371/journal.pgen.1004323)
2013
- Cater, M. A. et al., 2013. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chemical Biology 8 (7), pp.1621-1631. (10.1021/cb400198p)
- Pearson, H. B. 2013. Modelling metastasis in vivo. In: Madame Curie Bioscience Database. Georgetown TX: Landes Bioscience
- Pouliot, N. , Pearson, H. and Burrows, A. 2013. Investigating metastasis using in vitro platforms. In: Madame Curie Bioscience Database. Georgetown TX: Landes Bioscience
2011
- Pearson, H. B. et al. 2011. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. The Journal of Clinical Investigation 121 (11), pp.4257-4267. (10.1172/JCI58509)
2009
- Shorning, B. et al. 2009. Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine. PLoS ONE 4 (1) e4264. (10.1371/journal.pone.0004264)
- Pearson, H. B. , Phesse, T. and Clarke, A. R. 2009. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Research 69 (1), pp.94-101. http://dx.doi.org/10.1158/0008-5472.CAN-08-2895. (10.1158/0008-5472.CAN-08-2895)
2008
- Pearson, H. B. et al. 2008. Lkb1 defiency causes prostate neoplasia in the mouse. Cancer Research 68 (7), pp.2223-2232. (10.1158/0008-5472.CAN-07-5169)
- Pearson, H. B. 2008. Development and characterisation of novel mouse models of human prostate cancer. PhD Thesis , Cardiff University.
Adrannau llyfrau
- Pearson, H. B. 2013. Modelling metastasis in vivo. In: Madame Curie Bioscience Database. Georgetown TX: Landes Bioscience
- Pouliot, N. , Pearson, H. and Burrows, A. 2013. Investigating metastasis using in vitro platforms. In: Madame Curie Bioscience Database. Georgetown TX: Landes Bioscience
Erthyglau
- Brajdic, L. et al. 2025. Cutibacterium acnes: An emerging prostate cancer pathogen. Biology 15 (1) 30. (10.3390/biology15010030)
- Hodson, K. et al. 2025. Targeting cancer with Paris' arrow: An updated perspective on targeting Wnt Receptor Frizzled 7. Sci 7 (2) 61. (10.3390/sci7020061)
- Al-janabi, H. et al., 2024. Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer 12 (7) e009368. (10.1136/jitc-2024-009368)
- Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13 (8) 673. (10.3390/cells13080673)
- Chessa, T. A. et al., 2023. PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate. Molecular Cell 83 (16), pp.2991-3009. E13. (10.1016/j.molcel.2023.07.015)
- Owen, J. S. , Clayton, A. and Pearson, H. B. 2022. Cancer-associated fibroblast heterogeneity, activation and function: implications for prostate cancer. Biomolecules 13 (1) 67. (10.3390/biom13010067)
- Koushyar, S. et al. 2022. Exploring the Wnt pathway as a therapeutic target for prostate cancer. Biomolecules 12 (2) 309. (10.3390/biom12020309)
- Turnham, D. J. et al. 2020. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9 (11) 2342. (10.3390/cells9112342)
- Shorning, B. Y. et al. 2020. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. International Journal of Molecular Sciences 21 (12) 4507. (10.3390/ijms21124507)
- Flanagan, D. J. et al., 2019. Frizzled-7 is required for Wnt signaling in gastric tumours with and without Apc mutations. Cancer Research 79 (5), pp.970-981. (10.1158/0008-5472.CAN-18-2095)
- Pearson, H. B. et al. 2018. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth. Cancer Discovery 8 (6), pp.764-779. (10.1158/2159-8290.CD-17-0867)
- Martin, A. C. B. et al., 2017. [10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo. Oncotarget 8 (42), pp.72260-72271. (10.18632/oncotarget.20139)
- Liu, D. S. et al., 2017. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications 8 14844. (10.1038/ncomms14844)
- Rebello, R. J. et al., 2016. The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. Clinical Cancer Research 22 (22), pp.5539-5552. (10.1158/1078-0432.CCR-16-0124)
- Denoyer, D. et al., 2016. Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget 7 (24), pp.37064-37080. (10.18632/oncotarget.9245)
- Wölwer, C. B. et al., 2015. A chemical screening approach to identify novel key mediators of erythroid enucleation. PLoS ONE 10 (11) e0142655. (10.1371/journal.pone.0142655)
- Pearson, H. B. et al. 2015. The polarity protein Scrib mediates epidermal development and exerts a tumor suppressive function during skin carcinogenesis. Molecular Cancer 14 169. (10.1186/s12943-015-0440-z)
- Sampurno, S. et al., 2015. Myb via TGFβ is required for collagen type 1 production and skin integrity. Growth Factors 33 (2), pp.102-112. (10.3109/08977194.2015.1016222)
- Johnstone, C. N. et al., 2015. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Disease Models and Mechanisms 8 (3), pp.237-251. (10.1242/dmm.017830)
- Takizawa, I. et al., 2015. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget 6 (2), pp.604-616. (10.18632/oncotarget.2820)
- Elsum, I. A. et al., 2014. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo. Oncogene 33 (48), pp.5523-5533. (10.1038/onc.2013.498)
- Gödde, N. J. et al., 2014. Dissecting the role of polarity regulators in cancer through the use of mouse models. Experimental Cell Research 328 (2), pp.249-257. (10.1016/j.yexcr.2014.08.036)
- DiTommaso, T. et al., 2014. Keratin 76 is required for tight junction function and maintenance of the skin barrier. PLoS Genetics 10 (10) e1004706. (10.1371/journal.pgen.1004706)
- Phesse, T. J. et al. 2014. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration. Science Signaling 7 (345) ra92. (10.1126/scisignal.2005411)
- Phesse, T. J. et al. 2014. Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell Death and Differentiation 21 (6), pp.956-966. (10.1038/cdd.2014.15)
- Godde, N. J. et al., 2014. Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland. PLoS Genetics 10 (5) e1004323. (10.1371/journal.pgen.1004323)
- Cater, M. A. et al., 2013. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chemical Biology 8 (7), pp.1621-1631. (10.1021/cb400198p)
- Pearson, H. B. et al. 2011. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. The Journal of Clinical Investigation 121 (11), pp.4257-4267. (10.1172/JCI58509)
- Shorning, B. et al. 2009. Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine. PLoS ONE 4 (1) e4264. (10.1371/journal.pone.0004264)
- Pearson, H. B. , Phesse, T. and Clarke, A. R. 2009. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Research 69 (1), pp.94-101. http://dx.doi.org/10.1158/0008-5472.CAN-08-2895. (10.1158/0008-5472.CAN-08-2895)
- Pearson, H. B. et al. 2008. Lkb1 defiency causes prostate neoplasia in the mouse. Cancer Research 68 (7), pp.2223-2232. (10.1158/0008-5472.CAN-07-5169)
Gosodiad
- Pearson, H. B. 2008. Development and characterisation of novel mouse models of human prostate cancer. PhD Thesis , Cardiff University.
Ymchwil
Ffocws
Mae fy ymchwil i ganser y prostad yn integreiddio bioleg canser sylfaenol, darganfod biofarcwyr ac asesu cyn-glinigol dulliau therapiwtig newydd gyda'r nod terfynol o wella safon bresennol gofal cleifion. Mae'r ymchwil a gynhaliwyd yn defnyddio systemau model newydd i ymchwilio i yrwyr genetig cychwyn a dilyniant canser y prostad, a datblygu strategaethau therapiwtig arloesol ar gyfer canser y prostad.
Prosiectau a/neu themâu cyfredol
- Penderfynu sut mae'r llwybr WNT an-ganonaidd yn cyfrannu at ganser y prostad
- Amlinellu mecanweithiau moleciwlaidd ymwrthedd i therapi amddifadedd androgen
- Gwella effeithiolrwydd therapiwtig ataliad PARP ar gyfer trin canser y prostad
- Datblygu modelau clinigol perthnasol newydd ar gyfer canser y prostad
- Bôn-gelloedd canser y prostad a'r microamgylchedd tiwmor
- Archwilio sut mae signalau PI3K yn cyfrannu at ganser y prostad
- Ymchwilio i feddyginiaethau arbrofol newydd ar gyfer canser y prostad
Cyllidwyr
- Ymchwil Canser y DU (2020 - 2027)
- Ymchwil Canser y Prostad (2024 - 2027), (2025-2028), (2026-2029)
- Prostate Cymru: (2024-2027), (2026-2027)
- Canolfan Ymchwil Canser Cymru: (2025-2026)
- Ysgoloriaeth PhD Ymchwil Canser Cymru: (2025-2028)
- Prifysgol Caerdydd: (2024-2027)
Cydweithwyr
- Yr Athro Wayne Phillips (Canolfan Ganser Peter MacCallum, Melbourne, Awstralia)
- Yr Athro Owen Sansom (CRUK Beatson Institute, Glasgow, UK)
- Yr Athro John Staffurth (Canolfan Ganser Rutherford, De Cymru, DU)
- Yr Athro Gail Risbridger (Prifysgol Monash, Melbourne, Awstralia)
- Yr Athro Johann de Bono (ICR, Llundain, DU)
- Yr Athro Gareth Thomas (Prifysgol Southampton, y DU)
Staff Ymchwil
- Dr Tabitha Cunliffe
- Dr Anna Richards
- Dr Boris Shorning
- Mrs Lucy Hansen-Clarke
Myfyrwyr Ôl-raddedig
- Mr Samuel Hawkins (PhD)
- Miss Jess Hembrough (PhD)
- Mr Ben Mason (Meistri)
- Miss Madeleine Hilditch (Meistri)
- Alexander Marshall (cyd-oruchwylydd)
- Luka Brajdic (cyd-oruchwylydd)
- Phoebe Ross (cyd-oruchwylydd)
Cyn-fyfyrwyr:
- Dr Daniel Turnham
- Dr Marcos Qunitela
- Dr Nicholas Bullock
- Dr Manisha Mullen (Dass gynt)
- Dr Jasmine Owen
- Miss Sarah Martin
- Miss Katherine Mason
- Mr Raymond Brady (MSc)
- Mr Jamie Jenkins (MSc)
- Miss Erin Ffrangeg (IM)
- Miss Tegen Hooper (IM)
- Mr Ben Lund (IM)
- Miss Aeva Denise (MSc)
- Mr Harrison Beecham (MSc)
- Mr Harry Nelms (MSc)
- Miss Cerys Jones (IM)
- Miss Calitlin Green (IM)
- Miss Matilda Worthy (MSc)
Swyddi gwag
Holwch am ein swyddi cyfredol:
- Ysgoloriaethau PhD ar gael
- Swyddi myfyrwyr PhD clinigol ar gael
Addysgu
Addysgu israddedig
-
BI3352: Canser: Mecanweithiau moleciwlaidd, diagnosteg a therapiwteg, Dirprwy arweinydd modiwl a Darlithydd.
-
BI3001: Prosiectau Blwyddyn Olaf, Goruchwyliwr / Aseswr
-
BI9999: Blwyddyn Hyfforddiant Proffesiynol, Aseswr
- BIT152: Disease Dymamics, Darlithydd
- BI4001: Prosiectau myfyrwyr Meistr Integredig, Goruchwyliwr / Aseswr
Addysgu ôl-raddedig
- Prosiectau myfyrwyr MSc Bioleg a Therapiwteg Canser
- Myfyrwyr PhD
Bywgraffiad
Education and qualifications
I am a Cancer Research UK Research Fellow at the European Cancer Stem Cell Research Centre, Cardiff University. I graduated from the University of East Anglia in 2004 with a BSc in Biochemistry, following an exchange year at Colorado University (Boulder, USA). In 2004, I undertook my PhD at Cardiff University, where I developed several new models of prostate cancer, and moved to Australia to commence my post-doctoral training at the Peter MacCallum Cancer Centre in Australia. In 2012, I became an honorary fellow of Melbourne University and the inaugural Richard Pratt Foundation Fellow for prostate cancer research. In 2016, I returned to Cardiff University as a Marie Sklodowska-Curie Actions COFUND research fellow and was awarded a Cancer Research Career Development Fellowship in 2019, enabling me to build my research group investigating the molecular mechanisms that underpin prostate cancer growth and therapeutic resistance. This knowledge is applied to the development of novel and more effective biomarkers and therapeutic approaches for prostate cancer.
Anrhydeddau a dyfarniadau
- 2020 - 2027: Cymrodoriaeth Datblygu Gyrfa CRUK
- 2020: Gwobr Bwrsariaeth NCRI
- 2016 – 2020: Gweithredoedd Marie Slodowska Curie/Horizon2020/Cymrodoriaeth Ser Cymru II
- 2013 – 2014: Cymrodoriaeth Ymchwil Canser y Prostad Sefydliad Richard Pratt/Asiantaeth Canser Fictoraidd
Aelodaethau proffesiynol
Cymdeithas Ymchwil Bôn-gelloedd Awstralia (ASSCR)
2014 Grŵp treialon clinigol Wrogenol a Phrostad Awstralia a Seland Newydd (ANZUP)
2010 Cynghrair Ymchwil Canser y Prostad Awstralia a Chanada (AC-PCRA)
2005 Cymdeithas Ewropeaidd ar gyfer Ymchwil Canser (EACR)
Cymdeithas Ymchwil Canser Prydain (BACR) 2005
2004 Cymdeithas Frenhinol Bioleg (RSB)
Safleoedd academaidd blaenorol
2024 - presennol: Cyfarwyddwr Cyswllt, Canolfan Ymchwil Canser Cymru, Caerdydd, Cymru, DU
2020 - presennol: Arweinydd Grŵp, Labordy Ymchwil Trosiadol Canser y Prostad, Canolfan Ymchwil Bôn-gelloedd Canser Ewrop, Prifysgol Caerdydd, Cymru, DU
Penodiadau blaenorol:
2016 – 2020: Cymrawd Ymchwil, Canolfan Ymchwil Bôn-gelloedd Canser Ewrop, Prifysgol Caerdydd, Cymru, DU
2012 – 2016: Uwch Swyddog Ymchwil, Canolfan Ganser Peter MacCallum, Melbourne, Awstralia
2012 – 2016: Cymrawd er Anrhydedd, Prifysgol Melbourne, Adran Oncoleg Syr Peter MacCallum, Melbourne, Awstralia
2008 – 2012: Swyddog Ymchwil Iau, Canolfan Ganser Peter MacCallum, Melbourne, Awstralia
Pwyllgorau ac adolygu
Rolau golygyddol/adolygydd:
- Golygydd Gwadd Cyfnodolion, Biomoleciwlau
- Golygydd Gwadd Cyfnodolyn, PNAS
- Adolygydd Cyfnodolion, Cancer Discovery
- Adolygydd Cyfnodolion, Nature Communications
- Adolygydd Cyfnodolion, Modelau a Mecanweithiau Clefydau
- Adolygydd Cyfnodolion, Marwolaeth a Chlefyd Celloedd
- Adolygydd Cyfnodolion, Oncogene
- Adolygydd Cyfnodolion, Canser Moleciwlaidd
Rolau pwyllgor:
- Pwyllgor Cynghori Cymrodoriaeth Cyflymu Gyrfa Prostate Cancer UK
- Cymdeithas Prydain ar gyfer Ymchwil Canser, Aelod o'r Pwyllgor Gwaith
Meysydd goruchwyliaeth
Arolygiaeth
Ar hyn o bryd rwyf ar gael i oruchwylio myfyrwyr ymchwil ôl-raddedig (PhD, MRes, MSc).
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PhD ym meysydd:
- Bioleg foleciwlaidd canser y prostad
- Treialon cyn-glinigol ar gyfer canser y prostad
- Ymwrthedd therapiwtig mewn canser y prostad
- Metastasis
Goruchwyliaeth gyfredol
Prosiectau'r gorffennol
Myfyrwyr PhD wedi'u cwblhau:
- Dr Jasmine Owen (2021 - 2025): Archwilio rôl signalau PI3K ym microamgylchedd tiwmor y prostad
- Dr Nicholas Bullock (2018 - 2022, Cymrawd WCAT): Gwella effeithiolrwydd therapiwtig atalyddion polymerase polly (ADP-ribose) (PARP) mewn canser y prostad.
- Dr Manisha Mullen: (2018 - 2022, ysgoloriaeth PhD KESS2 / Tenovus): Amlinellu sut mae signalau oncogenig PI3K / PTEN yn cyfrannu at ganser y prostad.
Ymgysylltu
ArrayNews articles
Contact Details
Themâu ymchwil
Arbenigeddau
- Canser
